Literature DB >> 3219290

A prognostic classification of myelofibrosis with myeloid metaplasia.

G Barosi1, C Berzuini, L N Liberato, A Costa, G Polino, E Ascari.   

Abstract

The dependence of survival time on a set of prognostic factors was explored by means of Cox's regression model in 137 cases of myelofibrosis with myeloid metaplasia (MMM). The following parameters recorded at diagnosis proved to be important independent indicators of a poor prognosis: a higher value for age, a lower value for Hb concentration, a higher value for immature myeloid cells in peripheral blood (IMC), a lower value for total erythroid iron turnover (TEIT), and a bone marrow red cell aplasia (RCA). A prognostic classification tree was constructed whose terminal nodes (risk groups), described by simple logical conditions upon important indicators, were characterized by significantly different expected survival. The two extreme risk groups lend themselves to a simple, but complete description. The low-risk group (19.7% of the sample) comprises cases who had the diagnosis of MMM before age 45 and a number of IMC constantly lower than 24%. The actuarial proportion of patients surviving at 15 years was 100%. The high-risk group (29.9% of cases) comprises patients with age greater than 45 and Hb lower than 13 g/dl, associated with RCA, or with a relatively decreased erythropoiesis (TEIT lower than 2 times the normal) or with IMC greater than 24%. Seven out of the 11 who died within this group developed blastic crisis. Median survival time of the group was 69 months.

Entities:  

Mesh:

Year:  1988        PMID: 3219290     DOI: 10.1111/j.1365-2141.1988.tb02507.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 2.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

3.  Detection of erythroid hypoplasia in myelofibrosis using erythrokinetic studies.

Authors:  J E Howarth; H M Waters; K Hyde; C G Geary
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

4.  Comparative ferrokinetic study with initial and extended iron clearance models.

Authors:  J E Howarth; H M Waters; K Hyde; D Shanks; C G Geary
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

Review 5.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

6.  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Nam Lim; Gyeong-Won Lee; Sang-Min Lee; Nam-Kyung Lee; Jae-Cheol Choi; So-Yeon Oh
Journal:  Int J Hematol       Date:  2016-06-27       Impact factor: 2.490

7.  Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.

Authors:  Mohannad Abu-Hilal; Jayant Tawaker
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

Review 8.  Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies.

Authors:  Leopold Ohler; Klaus Geissler; Wolfgang Hinterberger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

9.  Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients.

Authors:  M C Souza; C A Rodrigues; M R R Silva; J Ribeiro; R Tognon; F A Castro; B P Simões; E X Souto; M L Chauffaille
Journal:  Med Oncol       Date:  2013-04-09       Impact factor: 3.064

10.  Myelofibrosis: Review of clinical and pathological features in fourteen dogs.

Authors:  B Hoff; J H Lumsden; V E Valli; S A Kruth
Journal:  Can Vet J       Date:  1991-06       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.